Taken together, these results suggest that Src and c-Abl are potential therapeutic targets in NB and that novel Src/Abl inhibitors like bosutinib alone or in combination with other chemotherapeutic agents may be promising treatment strategies for treating NB patients. The gene discussed is ABL1; the disease is neuroblastoma.